Toxicity of the typical antipsychotic haloperidol (HAL) comprises an apoptotic component that we link to pro-apoptotic Bcl-XS in PC12 preneuronal and N2a neuroblastoma cells. The mitochondrial translocation of Bcl-XS and its interaction with the pore-forming voltage-dependent anion channel (VDAC) correlates with the redistribution of cytochrome c and the cleavage of Poly(ADP-ribose) polymerase. Haloperidol-induced apoptosis is mediated by the sigma2 (s2) receptor system and does not involve the expected antagonism of the dopamine D 2 receptor, nor is it influenced by Vitamin E-or p53/Bax-mediated events. Pathological relevance is demonstrated by the cytotoxic synergism between HAL and the Alzheimer diseaserelated peptide b-amyloid(1-40), which correlates with Bcl-XS expression and its interaction with VDAC, and with cytosolic cytochrome c translocation. These data provide for a unique apoptotic mechanism that could underscore the clinical risks associated with HAL, particularly following chronic regimens or in the elderly.
Introduction
Haloperidol (HAL) is a typical antipsychotic still used in the treatment of many mental health issues worldwide, including predominantly for treatment of psychosis and, to a lesser extent, for major agitation in the elderly due to its 'calming' effects. In contrast to atypical antipsychotics such as olanzapine and quetiapine, HAL presents a questionable risk-benefit profile comprising extrapyramidal side effects, such as tardive dyskinesia. In the case of treatment of firstepisode schizophrenia, this may involve a neurodegenerative component 1 and significant decreases in whole brain gray matter (versus controls and olanzapinetreated patients), with differences being observed as early as 12 weeks in frontal gray and later on (52 weeks) in temporal and parietal lobes. 2 Persistent dopaminergic D 2 receptor blockade resulting in supersensitivity of postsynaptic dopaminergic receptor populations was originally thought to subserve these effects; 3 yet the noradrenergic, GABAergic and cholinergic neurotransmitter systems, as well as excess iron, oxidative stress and pyridinic metabolites have all been associated with antipsychotic-associated side effects. 4 More recently, the sigma (s) receptor, particularly the s2 receptor, has been forwarded as a candidate for the neurotoxicity associated with chronic antipsychotic treatment.
represent unique opioid and/or glutamatergic receptors, are actually distinct pharmacologically and molecularly defined receptors. They have recently been implicated in the etiology of schizophrenia and depression, as well as in agerelated changes in higher-ordered brain functions such as memory and learning. 7 s ligands comprise chemically unrelated drugs including HAL, pentazocine and di-otolylguanidine (DTG), and certain gonadal and adrenal steroids. 8 The s receptor has gained notoriety following the continued abuse by adolescent populations of the s ligand dextromethorphan-based cough syrups. 9 The s1 receptor exerts a putative protective role in cells exposed to stress and in models of depression, anxiety and psychosis. 7, 10 In contrast, the s2 receptor has been linked to apoptosis 5, 11 possibly via a mechanism that witnesses fluctuations in [Ca 2 þ ] i 12 and that is independent of the tumor suppressor protein p53.
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The Bcl-2 family of proteins consists of both antiapoptotic (including Bcl-2, Bcl-XL) and pro-apoptotic (including Bax, Bad, & Bcl-XS) molecules. Combinations of the various Bcl-2 homology domains (BH1-4) expressed in individual Bcl-2-related proteins dictate their respective anti-and pro-apoptotic properties. 13 Their distinct roles have made them the most well-defined regulators of the apoptotic process. It is well established that they exert many of their effects by modulation of cysteine protease (caspase)-dependent processes. Two distinct cascades contribute to apoptosis in the preneuronal PC12 cell line. One cascade is Bax-dependent and caspase-independent, while the other cascade is dependent on Bcl-XS, caspase and cytochrome c. 14, 15 The PC12 cell line is, therefore, a good in vitro model for examining the respective contribution of these cascades to drug-induced apoptosis. We have recently demonstrated that HAL can facilitate the mitochondrial redistribution of pro-apoptotic Bcl-XS, 16 which may explain HAL's limited neuroprotective potential in a variety of models of cytotoxicity when compared to newer generation (e.g. atypical) antipsychotics such as olanzapine and quetiapine (see Wei et al. 16 and references therein).
Several reports have linked in vitro HAL-induced cytotoxicity to vitamin E (antioxidant)-sensitive oxidative stress. 17, 18 We now demonstrate that HAL-induced cytotoxicity also comprises an apoptotic component that is linked to the redistribution of pro-apoptotic Bcl-XS to the mitochondria. This apoptotic effect, which we demonstrate can account for approximately 20% of HAL's total toxicity, is mediated by the s2 receptor, rather than by the expected interaction with the dopamine D 2 receptor. We suggest that conditions wherein s2 receptor function might prevail, as already suggested in models of aging or mood disorders, might sensitize cells to apoptotic insult. In support of this, we link Bcl-XS to the synergistic interaction between HAL and the Alzheimer disease-related peptide, b-amyloid . The contribution of psychotropic drugs to this cascade in the clinical setting needs to be considered.
Results

bcl-xS gene and gene product expression is induced selectively by haloperidol
Total cellular expression of Bax protein was increased by olanzapine (OLA), quetiapine (QUE) and HAL in PC12 cell extracts, while the expression of Bcl-XS was increased selectively by HAL (Figure 1a ). Semiquantitative reverse transcriptase-PCR (RT-PCR) reveals significant increases in bcl-xS mRNA expression, but little change in bcl-xL and bax mRNA expression (Figure 1b and c) . Mitochondrial levels of Bax, Bcl-XL and Bcl-XS protein are modestly affected by OLA and QUE treatment (Figure 2a ). In contrast, mitochondrial extracts from HAL-treated cell cultures have significantly less Bax immunodetection, while those of Bcl-XL and, more importantly, Bcl-XS are increased (Figure 2a) . The increased mitochondrial Bcl-XS levels correlate with the cytosolic translocation of cytochrome c as well as with the cleavage of the activator protease caspase-9 and of PARP, a possible caspase-3 substrate (Figure 2b ). The r 2 receptor, Bcl-XS and apoptosis
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Mitochondria-mediated apoptotic cascades can depend on modulation by Bcl-2-related proteins of VDAC function and pore-forming capacity. We now provide unique evidence that treatment of PC12 cells with HAL results in a complex that contains both Bcl-XS and VDAC ( Figure 2c ). As VDAC expression remains unchanged (Figure 2c ), the interaction is more likely a reflection of the greater availability of Bcl-XS, particularly in the mitochondria (see Figure 2a) . We chose to focus on the apoptotic effect of HAL.
Bcl-XS protein expression induced by haloperidol is independent of the transcriptional activator, p53 bax mRNA expression increased by 1 h of HAL treatment and parallels changes in mRNA and protein expression of the transcriptional activator, p53 (Figure 3a and b) . In contrast, significant changes in bcl-xS mRNA and protein levels occur later, for example, between 8 and 24 h (Figure 3a and b) . p53 has been linked to tumor suppression/apoptosis apparently by way of enhanced Bax expression. 19 Overexpression of the dominant negative p53-V143A construct does abrogate HAL-induced Bax expression, but does not affect either HAL-induced cell death (Figure 3c ) or the concurrent increase in the expression of Bcl-XS (Figure 3d ). These data preclude a role for a p53/Bax-dependent cascade 14 in our model.
Overexpression of Bcl-XS sensitizes PC12 cells to haloperidol toxicity Overexpression of FLAG epitope-tagged Bcl-XS (Figure 4a ) promotes HAL-induced cell death ( Figure 4b ) and clearly supports a pivotal role for a Bcl-XS-dependent cascade. The r 2 receptor, Bcl-XS and apoptosis
Pharmacological receptor profiling of HAL's effects
Having implicated the Bcl-XS-dependent cascade with HALinduced apoptosis, we shifted our focus to the potential receptor system(s) involved. Haloperidol is classically associated with dopamine D 2 receptor antagonism, 3 yet this receptor does not appear to mediate effects in the current model as the dopamine D 2 receptor-selective antagonist, sulpiride, does not affect cell viability (Figure 5a ). A clear alternative is the s receptor system, which displays a high affinity for HAL. We continued to use the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) conversion assay as an effective, non-radiometric means of defining cell viability and the pharmacological interaction(s) between the selected drugs.
The s1 receptor agonists 1,3-di-o-tolylguanidine (DTG; mixed s1/s2 agonist, with a much greater affinity for s1) and SKF 10,047 (( þ )N-allyl-normetazocine, SKF; s1-selective agonist) do not affect cell viability, whereas HAL and the s ligand rimcazole both decrease cell viability in a concentration-dependent manner (Figure 5a ). Furthermore, DTG and SKF 10,047 both induce an upward shift in the response curve to HAL (Figure 5b ). We confirm this to be non-competitive antagonism by the change in slope on a double-reciprocal plot (Figure 5b , insert), which reveals a diminished potency in the presence of DTG, that is, the HAL þ DTG line is higher than the HAL (alone) line, and an unaltered affinity, that is, the two lines intersect. Sulpiride does not impact the effect of HAL ( Figure 5b ) and confirms this cascade to be independent of dopamine D 2 receptor antagonism. The rank-order potency of sigma ligands, for example, rimcazole4HAL444DTG ¼ SKF (Table 1) , implicates the s2 receptor 11 as the primary determinant in HALinduced apoptosis. To demonstrate that these s ligands are exerting their functional effects by competing for distinct s receptors, we treated PC12 cells with 150 mM of HAL and increasing concentrations of SKF 10,047. The resultant biphasic curve (Figure 5c ) is reminiscent of data used by Musacchio et al. 20 to support their allosteric model (i.e. activation of the s1 receptor alters the subsequent binding/ function of an adjacent s2 receptor). In support of a primary role for Bcl-XS in this model, rimcazole treatment results in significantly higher Bcl-XS expression than treatment with HAL (while DTG elicits no significant change over control). These data are corroborated by the cleavage of PARP to the p85 fragment in the HAL-and rimcazole-treated cellular extracts (Figure 5d) .
A similar rank-order potency profile is observed in the neuroblastoma N2a cell line (Figure 5e ), but a leftward shift in the response curves indicates a greater potency of these drugs in these cell cultures ( Table 1 ). The inability of the s1-selective agonist SKF to block the effects of HAL (Figure 5f ) suggests a non-functional s1 system. This would explain the emergent toxicity of the mixed s1/s2 agonist DTG, which in the absence of a functional s1 receptor system (and in support of our hypothesis) would act as a pure s2 receptor agonist and exert cytotoxicity (Figure 5e ). This further suggests indirectly that functional s1 receptors might normally 'mask' or 'blunt' cytotoxic effects mediated by the s2 receptor. The putative protective (see masking) role of s1 receptor activation is confirmed by treating PC12 cell cultures with the hormone progesterone (PROG), a potent s1 receptor antagonist. 8 A high concentration of the s agonist DTG, for example, 400 mM, which by itself has only marginal effects on cell viability (Figure 5a and g ), significantly decreases cell viability in the presence of PROG (Figure 5g ). We conclude that functional attenuation of the s1 receptor system, for example, as in N2a cell cultures or with PROG, 'unmasks' the cytotoxicity of s2 receptor activation.
Haloperidol induces both (s-sensitive) apoptosis and (s-insensitive) oxidative cell death
We validated the effects of HAL on PC12 cell death; DTG was able to inhibit the HAL-induced increase in apoptotic (sub-G 1 ) cells (Figure 6a ). This is independent of any change in cell cycle (Figure 6b ), thus indirectly supporting our observation that this event is not mediated by p53 (see Figure 3c and d), which is often associated with cell cycledependent apoptosis. 19 Lactate dehydrogenase (LDH) release, as an independent measure of cell death, is significant following treatment with HAL and is sensitive to DTG (Figure 6c) . Furthermore, the cell death, for example, decreased MTT conversion, elicited by HAL is comprised of two distinct components with one being sensitive to DTG and the other to the antioxidant vitamin E (VitE) and with their combined effects being additive (Figure 6d ). Thus, DTG influences a priori the apoptotic component (B15%) and not the VitE-sensitive (oxidative stress) component of HAL- Haloperidol promotes toxicity of the Alzheimer disease-related peptide b-amyloid (1-40) Haloperidol can exacerbate behavioral and psychomotor dysfunction in patients with Alzheimer disease. 24 We examined whether Bcl-XS might be implicated in this event. The concentrations of HAL (100 mM) and of the Alzheimer disease-related peptide Ab40 (30 mM) are not significantly toxic over the treatment interval (Figure 7 ) (confirms previous observations; for HAL, see above, while demonstrable Ab40 toxicity requires a longer interval, see Mousseau et al. 25 ). The HAL þ Ab40 combination, however, is toxic. This coincides with an increase in Bcl-XS protein expression and a pronounced interaction between Bcl-XS and VDAC as well as increased cytosolic cytochrome c immunodetection (Figure 7 ).
Discussion
It is becoming clear that the dopamine D 2 occupancy model cannot account entirely for the risk-benefit profiles of antipsychotics. 26 The s receptor system is being considered as an alternative candidate. However, the molecular mechanisms that might account for either the 'modulatory' role of the s1 receptor 7 or for the apoptotic role of the s2 receptor 5 are unclear and may be hampered by the fact that only the s1 receptor has been successfully cloned. 27 We focused on the typical antipsychotic HAL as it presents a significant neurotoxic profile and as it targets predominantly the dopamine D 2 and the s receptor systems. This allowed us to determine the respective receptor's contribution to our recently posited HAL/Bcl-XS-mediated cell death cascade. 16 The concentrations of HAL used herein were higher than the range of maximum levels detected in patient brain tissue (e.g. 10 mM
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), but are in keeping with concentrations required elsewhere to examine the molecular effects of HAL in the experimental setting. 10, 16, 29, 30 These studies are underscored by the pervasive and questionable use of HAL in the treatment of diverse mental health issues worldwide. The lack of effect of the s1-selective ligand, SKF, on HAL-induced cytotoxicity indicates a functionally compromised s1 receptor system in these cells (('): HAL alone; (J): HAL þ 50 mM SKF). Indeed, s1 receptor immunodetection is comparable in both PC12 and N2a cell lysates (densitometric analysis indicates relative s1 receptor to b-actin ratios (n ¼ 2) of 1.00 (PC12) and 1.04 (N2a)) (f, insert). (g) The putative protective role of the s1 receptor as well as its ability to mask the toxic effects of s2 receptor activation is revealed by co-treatment of PC12 cell cultures with DTG (400 mM, 2 days) and the s1 receptor antagonist progesterone (PROG; 50 mM, 1 h pretreatment: n ¼ 6-12, *: Po0.05 & ***: Po0.001 versus vehicle control).
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We recently demonstrated that HAL induces the mitochondrial accumulation of Bcl-XS in PC12 cells 16 and now link this to the redistribution of cytochrome c and to hallmarks of apoptotic processes, that is Annexin-V staining as well as the cleavage of caspase-9 (present study and Lindenboim et al.
14 and Braun et al. 31 ) and of PARP (oftentimes considered a caspase-3-dependent process, although exceptions are known: Yu et al.
32
). It is well known that the various Bcl-2 homology (BH1-4) domains dictate the distinct functions of Bcl-2-related proteins. 13 For example, the BH3 domain-binding groove of anti-apoptotic members such as Bcl-2 and Bcl-XL helps to sequester BH3 domain-containing pro-apoptotic homologs and, thus, to preserve mitochondrial function. While Bcl-2 homologinduced modulation of cytochrome c release from mitochondria often reflect channel formation by pro-apoptotic Bcl-2 homolog dimers, hybrid channels formed by association with the voltage-dependent anion channel (VDAC; a component of the mitochondrial permeability pore) cannot be discounted. [33] [34] [35] We now reveal an interaction between Bcl-XS and VDAC that is promoted by HAL treatment. Furthermore, overexpression of Bcl-XS can potentiate HAL's toxicity, while overexpression of anti-apoptotic Bcl-XL partially reverses HAL's effects (data not shown), which confirms a BH3-dependent apoptotic process. 31, 36 These data also corroborate reports of Bcl-2/Bcl-XL-sensitive antipsychotic- 37 and Bcl-XS-mediated 14 cytotoxicity. The present s2/Bcl-XS-mediated apoptotic component consistently accounts for approximately 20% of HAL's cytotoxicity (and, thus, may be overshadowed by the more pronounced Vitamin E-sensitive oxidative stress-associated component already described 4, 17, 18 ). Although our functional data reveal a rank-order potency reminiscent of s2 receptor activation, 11, 38 for example, rimcazole4HAL444DTG ¼ SKF, this does not necessarily reflect the rank-orders obtained by standard radioligand binding studies (see Table 1 ). Indeed, even pharmacologic profiles for an individual receptor determined by radioligand binding studies often do not concord and may reflect different s1 or s2 receptor subtypes, strain, species and tissue differences, possible allosteric modulation and even non-specific binding to metabolic enzymes. 20, 21, 39 Functional studies oftentimes contribute to the confusion as many such studies rely on HAL for its presumed capacity as a s receptor 'antagonist', whereas it has been clearly shown that HAL can act as a s2 receptor agonist in certain cases (present study). 11, 38 Any discrepancy between functional and binding data could simply reflect the differential ability of s2 ligands to access intracellular s2 receptors, as suggested by Vilner et al., 12, 29 or could reflect blunting of the s2 effect by simultaneous activation of the s1 receptors as demonstrated presently with DTG (and evidenced indirectly by our N2a neuroblastoma cell cultures, which do not respond to s1 receptor activation and are much more sensitive to HAL). The atypical antipsychotics OLA and QUE do not initiate the Bcl-XS-mediated mechanism, which corroborates our demonstrations of greater neuroprotective potential of atypical antipsychotics, versus the more traditional HAL, in several models of cell death/stress (see Wei et al. 16 and references therein). It is also possible that this The r 2 receptor, Bcl-XS and apoptosis Z Wei et al mechanism contributes to the reductions in whole brain gray matter observed during treatment of first-episode psychosis with HAL, but not with olanzapine. 2 The affinity of atypical antipsychotics for s receptors remains unknown.
Both OLA and QUE induced pro-apoptotic Bax expression (with little change in bax mRNA). While this suggests a posttranscriptional influence of these drugs, it also demonstrates that Bax expression itself is not a dependable qualitative measure of mitochondrial-mediated cytotoxicity. It is quite possible that any potential toxicity mediated by Bax could be negated by the concurrent mitochondrial relocalization of anti-apoptotic Bcl-XL during treatment with these atypical antipsychotics. We were able to demonstrate that the modest increase in pro-apoptotic Bax induced by HAL was linked to p53 transcriptional activity, as expected. 19 However, the p53 system could not be linked to bcl-xS gene and protein expression or on the resultant loss of cell viability. Interestingly, the HAL-induced increase in total cellular Bax did not result in a proportional increase in mitochondrial Bax, thus supporting a negligible role for Bax in our model as well as a possible influence by HAL on Bax conformation, oligomerization or cleavage of Bid, an activator of Bax-mediated apoptosis. 19 It is known that Bax can contribute to mechanisms independent of mitochondrial cytochrome c release. 40 Therefore, events triggered parallel to, but not dependent on, mitochondrial dysfunction could include the prominent Vitamin E-sensitive event that we and others 17, 18 have associated with HAL's toxicity. Although this is a purported Bax/p53-dependent mechanism, 18 we were unable to affect the change in HAL-induced cell death by overexpressing dominant negative p53 in PC12 cells (and also in N2a cells, data not shown), although we could with Vitamin E. Furthermore, we were unable to induce cell cycle arrest, which has been closely linked with p53 activity, 19 by treatment with HAL. Perhaps the role of p53 in HAL-induced cell death is more subtle and is not detectable by any of the assays used herein. Post et al. 18 have demonstrated that HAL treatment can increase nuclear binding of the transcription factor NF-kB and correspondingly can decrease the activation of the NF-kB inhibitor, IkBa, which they propose might account for the changes in Bax expression. Our own studies confirm a HAL-induced increase in IkBa phosphorylation, but, in contrast, reveal an almost complete abrogation of NF-kB binding to nuclear extracts (manuscript in preparation). Interestingly, abrogated NF-kB binding has been linked to a p53-independent, caspase-dependent death mechanism that is sensitive to ectopic Bcl-XL expression. 41 As our data do not concord with those of Post et al., 18 the roles of IkBa and NF-kB in HAL-induced cytotoxicity remain unclear. The discrepancies in our respective data sets might be explained simply by the homo-or heterogeneity of the cell population being evaluated, for example, a preneuronal clonal cell line (used herein) versus whole tissue extracts (used by Post et al. 18 ). A link between neuroprotective potency and s1 receptor affinity is demonstrated in models of depression, anxiety, psychosis and cytotoxicity. 7, 10 The molecular cascade we describe supports a 'modulatory' role for the s1 receptor as it exerts no discernable inherent molecular effect, but consistently reverses the cytotoxic effects of s2 receptor The r 2 receptor, Bcl-XS and apoptosis Z Wei et al activation. Given the contrasting contribution of these two receptors to cell viability, we must consider the functional relevance of the Bcl-XS-based cascade. There are reports of increased s1 receptor densities in aged brain (e.g. rat, monkey) suggesting compensation for decreased availability of the endogenous ligand, 42 which may include dehydroepiandrosterone, pregnenolone, progesterone and other neurosteroids. 8, 43 The loss of s1 receptor ligand and, by implication, diminished s1 receptor function would obviously sensitize local cell populations to apoptotic processes, particularly in a system witnessing chronic (antipsychotic-mediated?) s2 receptor activation. Although it is difficult to extrapolate from our cell-based data to the human condition, the exacerbation of psychomotor, behavioral and cognitive dysfunction by typical antipsychotics, including HAL, both in healthy elderly volunteers and in Alzheimer disease patients 24, 44 may reflect s receptorsensitive cascades, for example, a compromised s1 receptor system and/or an activated s2 receptor system (present study and Gil-Ad et al. 45 ). Support for this is limited, but recent animal studies suggest that s1 receptor agonists may be useful in alleviating learning and memory impairment in aged rats or mice, or in rodents injected centrally with the Alzheimer-related peptide b-amyloid (Ab) (see Phan et al. 46 and references therein). Furthermore, s1 receptor agonists may mitigate clinically relevant depression associated with, and a possible risk factor for, Alzheimer disease. 47 In addition, neuronal apoptosis induced by the Ab (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) fragment was recently shown to downregulate the expression of two anti-apoptotic Bcl-2 homologues, namely Bcl-w and Bcl-XL. 48 The synergism we demonstrate between HAL and the Ab(1-40) peptide, which correlates with increased detection of Bcl-XS and of a Bcl-XS-VDAC complex that coincides with an increase in cytosolic cytochrome c, could have serious impact in the clinical setting.
The unique cascade we describe relies on s1 receptors effectively mitigating a s2 receptor-induced toxicity mediated by pro-apoptotic Bcl-XS. This cascade might subserve the toxicity associated with HAL as well as with other s ligand/psychotropics given our results obtained with rimcazole. It may also play a prominent role in the riskbenefit profile associated with typical antipsychotic regimens, particularly in elderly patients with an underlying neurodegenerative condition.
Materials and methods
Chemicals and antibodies
Anti-VDAC was purchased from Calbiochem (San Diego, CA, USA). Anti-cytochrome c was purchased from BD Biosciences (Mississauga, ON, Canada). s1 receptor antiserum was a gift from Dr T-P Su (NIDA, NIH). Anti-b-actin, HAL, DTG, rimcazole and SKF 10,047 were obtained from Sigma-Aldrich (Oakville, ON, Canada). b-Amyloid(1-40) was purchased from BIOSOURCE (Camarillo, CA, USA). All other antibodies were purchased from Santa Cruz Biotechnology.
Cell culture and experimental treatments
The rat preneuronal pheochromocytoma PC12 cell line (CRL-1721) and mouse neuroblastoma Neuro-2a [N2a] cell line (CCL-131) were obtained from ATCC. Cell lines were cultured (5% CO 2 at 371C) in RPMI 1640 medium containing 5% fetal bovine serum, 100 IU/ml penicillin G sodium salt and 0.03% glutamine. The medium was supplemented with 10% horse serum for PC12 cell culture. Cells were treated in log phase. 0 . The resultant PCR products were electrophoresed and visualized using ethidium bromide staining, and densitometric analysis was 
Western blot analysis and immunoprecipitation
Precleared cellular extracts were either immunoprecipitated with specific antibodies or directly denatured for analysis by standard Western blotting techniques. Protein expression was visualized by enhanced chemiluminescence.
Subcellular fractionation
Treated cells were harvested, washed twice with 0.1 M icecold PBS, pelleted, and then resuspended in ice-cold buffer containing 20 mM Hepes-KOH (pH 7.5), 320 mM sucrose, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM dithiothreitol, 1 mM orthovanadate and protease inhibitors. Cells were disrupted using a Dounce homogenizer and the homogenates were centrifuged at 900 g (10 min, 41C). The resultant supernatant was then centrifuged at 18 000 g (40 min, 41C) and the pellet is the mitochondria-enriched fraction, while the supernatant represents the cytosolic fraction.
Plasmid DNA and transient transfections pC53SCX3 (a p53 cDNA bearing a Val143Ala codon substitution) expresses a dominant negative, full-length human p53 (a gift from Dr F Wyllie, University of Wales, Cardiff; with permission from Dr B Vogelstein, Johns Hopkins University, Baltimore). Wild-type Bcl-XS was amplified from PC12 cDNA and subcloned in-frame with an N-terminal triple-FLAG epitope. Wild-type human Bcl-XL was a generous gift from Dr RJ Youle (NINDS, NIH). Cells were seeded in log phase and transfected with plasmid DNA (1-2 mg/well on a 24-well plate; seeded at 5 Â 10 5 cells/well) using LipofectAmine Plus (Invitrogen Life Technologies).
Cell viability parameters (MTT conversion, LDH release and flow cytometry) MTT dye conversion was used as a non-radiometric index of mitochondrial function and cell viability as described previously. 16 Extracellular LDH activity reflecting increased plasma membrane permeability was also estimated in parallel according to the manufacturer's protocol (Roche Diagnostics). Propidium iodide and Fluorescence-activated cell sorting was used to examine phases of the cell cycle and apoptotic cell death (sub-G 1 populations).
Statistical analysis
All data points are expressed as mean7s.e.m. Significance (Po0.05) was assessed by ANOVA with post hoc analysis relying on Bonferroni's Multiple Comparison Test. 
